May 9, 2016 — Gamma Medica, provider of molecular breast imaging technology (MBI), announced it has launched the Be Certain campaign, featuring a dedicated microsite as the cornerstone of an initiative to spread awareness on breast density.
Today, about half of all women in the United States have dense breast tissue, making them four to five times more likely to develop breast cancer. Traditional screening technology alone is not advanced enough to accurately detect cancerous tumors for these women who have a higher intrinsic risk of developing cancer during the course of their lifetime.
The goal of the campaign is to confront the 40,000 deaths annually at the hands of breast cancer by empowering women to be proactive about their breast health and consult their doctors to gain a better understanding of risks associated with dense breast tissue. The microsite provides patients with a one-stop educational resource with the most updated, accurate information for women with dense breast tissue, allowing them to Be Certain about their screening results and the latest clinical data on breast cancer.
With the Be Certain campaign, Gamma Medica aims to shift the public conversation on breast cancer awareness by educating patients, physicians, breast surgeons, radiologists and the industry about how MBI can increase detection rates by 400 percent and offer other benefits when used as a supplemental screening tool to the traditional mammogram. Visitors will have access to accurate information and statistics, testimonials and patient stories.
For more information: www.becertain.info
July 30, 2024 
